Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has...
Pharmaceutical
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic, targeted oncology...
NuGen Medical Signs 5-Year Distribution Agreement for InsuJet(TM) with Advance Medical Life Co.
Toronto, Ontario--(Newsfile Corp. - December 14, 2023) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading...
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update
PRINCETON, NJ / ACCESSWIRE / December 14, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical...
Hope On The Horizon: Tonix Pharmaceuticals (NASDAQ:TNXP) Could Be On the Cusp of Changing Fibromyalgia Treatment Options With TNX-102 SL
Topline Data from a Registration-Enabling Phase 3 Clinical Trial is Due Later This Month.CHATHAM, NJ / ACCESSWIRE / December 14,...
Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)
Revolutionary, micro-invasive, injectable treatment for the full range of glaucoma disease severity iDose TR was designed to usher in a...
Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus Keytruda at Three Years
At a median planned follow-up of approximately three years, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence...
Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)
SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx, (NASDAQ: AMAM), today announced that the Company...
Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases
Journal of Nanobiotechnology publication describes results from the successful Phase 2 REPAIR clinical studies that measured changes in brain energy...
ASTCT Response to FDA Approval of Gene Therapies for Treatment of Sickle Cell Disease (SCD)
CHICAGO, IL / ACCESSWIRE / December 13, 2023 / The American Society for Transplantation and Cellular Therapy® (ASTCT®) recognizes the...
BioHarvest Sciences Announces Major Product Launch of VINIA-Based Functional Coffees
VINIA Superfood Coffee will be a unique disruptor in the $6B US coffee pod marketFirst of three Major "VINIA Inside"...
Lynx.MD and Baptist Health Innovations Collaborate to Advance Medical Research and Development
Initiative enhances Baptist Health South Florida's efforts in medical innovation for advanced research and collaborative development.PALO ALTO, CA / ACCESSWIRE...
SELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ET
NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a...
Halberd Corporation Signs Multi-Faceted Agreement with CrodenHealth.com
Peter Croden, CrodenHealth Chairman, previously executive with Pharmacia & Upjohn (Pfizer), Upjohn Canada, Upjohn Global Animal Health, NephRx, and Parnell...
Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis
NEWARK, CA / ACCESSWIRE / December 13, 2023 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced it has...
Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome
Positive initial data and clean safety profile catalyze optimization planSize of both ongoing clinical trials significantly increasedLower dose eliminated from...
Juva Life Reports Strong Growth in Q3 2023 Financial Results
REDWOOD CITY, CA / ACCESSWIRE / December 13, 2023 / Juva Life Inc. (CSE:JUVA)(OTCQB:JUVAF)(FRANKFURT:4VV) ("Juva Life" or the "Company"), Juva...
Calyxo Closes on $50 Million Equity Financing to Support Broad Launch of CVAC Kidney Stone Treatment
Investment Round will Fund Expansion of Commercial Team and Further Product DevelopmentPLEASANTON, Calif.--(BUSINESS WIRE)--#CVAC--Calyxo, Inc., a medical device company developing...
MATTER opens applications for accelerator focused on reducing maternal mortality in the U.S.
Health Care Service Corporation, Laerdal Million Lives Fund, BayCare, Parkview Health, University of Chicago Medicine, Organon and Stryker to support...
Pressure BioSciences’ UltraShear Platform Maintains Nutritional, Sensory, and Other Important Qualities of Liquid Foods While Inactivating Foodborne Bacterial Spores
Novel Results Published in Respected Peer-Reviewed Food Science and Emerging Technologies Journal - Discussions Underway with Beverage Industry CompaniesSOUTH EASTON,...